Accreditation

Continuing Medical Education (CME)

General Information

● 2025 Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Annual Meeting (2025 CGA IGC Annual Meeting)
● October 9-11, 2025 / Hyatt Regency, St. Louis, MO
● Jointly provided by Postgraduate Institute for Medicine and Collaborative Group of the Americas on Inherited Gastrointestinal & Kenes Group

Target Audience

● This activity is intended for genetic counselors, physicians, scientists, advanced practice providers, psychologists, and nurses who seek state-of-the-art updates in the prevention, diagnosis, and treatment of patients with hereditary gastrointestinal cancer syndromes.

Educational Objectives

After completing this activity, the participant should be better able to:
● Summarize societal guidelines that have expanded access to hereditary cancer testing for a broader patient population
● Identify insights gained from diverse clinical experiences to optimize genomic testing workflows in hereditary cancer populations to ensure timely informed care and treatment.
● Summarize the impacts of a mainstreaming program on a colorectal surgery clinic and overall colorectal cancer oncology program.
● Evaluate the outcomes of current criteria for genetic testing for polyposis and hypothesize on potential other characteristics that could be used to improve this in future
● Describe how assay developments such as long-read sequencing can reduce missing heritability
● Explain the principles of Parent-of-Origin-Aware genomic analysis, including how it differs from traditional genetic testing methods
● Discuss the current and emerging clinical data on the advantages, disadvantages, accuracy and utility of the most promising early detection tests available for pancreatic cancer
● Debate the rationale for lung cancer screening in individuals with Peutz-Jeghers syndrome
● Describe the utility of chemoprevention and endometrial biopsy for uterine cancer in Lynch Syndrome
● Compare and contrast the clinical management strategies of cancer surveillance and prophylactic surgery in CDH1 variants carriers
● List cancer surveillance considerations for transfeminine or transmasculine patients with Lynch syndrome compared to cisgender patients
● Illustrate barriers to chemoprevention of hereditary cancers by modeling uptake of aspirin (ASA) and NSAIDS in Lynch syndrome (LS)
● Discuss surgical options for hysterectomy, salpingectomy, and oophorectomy based on specific Lynch Syndrome genes
● Compare the pros and cons of extended colectomy by the affected MMR gene
● Evaluate the influence of preoperative Lynch syndrome diagnosis on the extent of surgery in patients with colon cancer

Disclosure of Conflicts of Interest

See Financial Disclosure document.

Joint Accreditation Statement